Investigation of Patient Benefits With a New Supporting Ostomy Product in Patients With a Newly Stoma Formation
Launched by COLOPLAST A/S · Nov 22, 2021
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Have provide written informed consent.
- • 2. Be at least 18 years of age and have full capacity.
- • 3. Have had their stoma for less than 9 months.
- • 4. Have intact skin on the peristomal area (assessed by investigator)
- • 5. Be able to use one of the five test products (i.e. Ø40, Ø50, Ø60, Ø70, Ø80 mm)
- • 6. Ileo- or colostomists with liquid and/or mushy output (Bristol scale type 5-7)
- • 7. Is willing to refrain from use of paste and protective sheets.
- • 8. Have a smartphone applicable for the HeyloTM app.
- • 9. Have been self-managing stoma appliance for at least 14 days.
- • 10. Are able to follow study procedures for 3 months (assessed by investigator)
- • 11. Are willing to receive their ostomy products through Coloplast Charter for the duration of the study.
- Exclusion Criteria:
- • 1. Currently receiving or have within the past month received topical steroid treatment in the peristomal skin area or systemic steroid (tablet/injection) treatment.
- • 2. Is breastfeeding.
- • 3. Is pregnant based on urine pregnancy test.
- • 4. Enrolled in another current research study or have previously participated in this investigation.
- • 5. Has known hypersensitivity towards any of the products used in the investigation.
- • 6. Is using/have a pacemaker.
- • 7. Has a complicated stoma at baseline (dehiscence/prolapse/hernia)
- • 8. Has limited life expectancy or receive palliative care.
- • 9. Has stage 4 cancer.
- • 10. Having more than one stoma synchronously
- • 11. Having ongoing non-healed abdominal wounds
- • 12. Reoperation / stoma reversal planned during the study period.
About Coloplast A/S
Coloplast A/S is a leading global medical device company headquartered in Denmark, specializing in products and services for individuals with intimate healthcare needs. With a strong commitment to innovation, Coloplast develops solutions in areas such as ostomy care, urology, and wound care. The company prioritizes patient-centered design, combining advanced technology with user-friendly applications to enhance quality of life for patients. Coloplast A/S actively conducts clinical trials to validate the safety and efficacy of its products, ensuring they meet the highest standards of care and contribute to improved health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Newcastle, , United Kingdom
Bristol, , United Kingdom
Chelsea, , United Kingdom
Exeter, , United Kingdom
Great Yarmouth, , United Kingdom
Leeds, , United Kingdom
Manchester, , United Kingdom
Middlesbrough, , United Kingdom
Peterborough, , United Kingdom
Preston, , United Kingdom
Patients applied
Trial Officials
Richard Brady
Principal Investigator
Newcastle-upon-Tyne Hospitals NHS Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials